ACTRN12614001315606进行中（未招募）2 期
A phase II study assessing the intracranial response to nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 79
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Cohort 1 and 3
- •Inclusion criteria
- •1. equal or greater than 18 years of age.
- •2. Written informed consent
- •3. AJCC Stage IV (any T, any N, M1c) histologically confirmed melanoma or unknown primary melanoma. Patients must have at least 1 radiological definitive brain metastasis that is equal or greater than 5mm and equal or less than 40mm measurable per RECIST version 1.1 guidelines.
- •4. In patients with prior BRAF inhibitor treatment, intracranial disease progression must be demonstrated (RECIST greater than 20% or new measurable brain metastases) compared with nadir of intracranial response during BRAF inhibitor treatment, and confirmed with a second MRI brain scan at any time from the beginning of the drug washout period (dabrafenib = 5 days, trametinib = 14 days).
- •5. No prior localised treatment for brain metastases (eg. surgery or radiotherapy).
- •6. Neurologically asymptomatic from brain metastases.
- •7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, and life expectancy greater than 30 days.
- •8. Able to undergo MRI with Gadolinium contrast agent.
- •9. Adequate haematological, hepatic and renal organ function.
- •10. Women of childbearing potential: negative serum pregnancy test and effective contraception from 14 days prior to study treatment until 23 weeks after the
- •11. Men with female partner of childbearing potential to use effective
- •contraception from 14 days prior to study treatment until 31 weeks after the last dose.
- •Cohort 2 - per Cohorts 1 & 3, except patients must have at least one of the following:
- •1. Failed prior local therapy for brain metastases (including surgery, stereotactic radiotherapy or whole brain radiotherapy) where disease has progressed per RECIST (greater than 20% increase in SOD or new measurable brain metastases),
- •2. Have current neurological symptoms related to brain metastases. IF they have received prior local therapy for brain metastases, the disease must have progressed per RECIST (greater than 20% increase in SOD or new measurable brain metastases),
- •3. Have leptomeningeal disease concurrently with measurable brain metastases. IF they have had failed prior local therapy for brain metastases, this must have progressed per RECIST (greater than 20% increase in SOD or new measurable brain metastases).
排除标准
- •Exclusion criteria
- •1. Any melanoma brain metastasis greater than 40mm and any leptomeningeal disease, whether asymptomatic or not.
- •2. Ocular melanoma.
- •3. Prior treatment with an anti-PD-1 or anti-PD-L1 , anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- •4. Patients with active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- •5. Current systemic treatment with corticosteroids, except prednisone at nonimmunosuppressive doses of less than or equal to 10 mg/day (or equivalent). Past treatment for non-neurological symptoms allowed, if ceased 2 weeks prior to starting study
- •treatment. Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if patient on a stable dose. Non-absorbed intra-articular steroid injections will be permitted.
- •6. Any investigational drug or other systemic drug therapy for melanoma within 28 days or 5 half-lives from baseline.
- •7. Known to be HIV positive, or a positive test for hepatitis B and C.
- •8. Another malignancy or concurrent malignancy unless disease-free for 3 years.
- •9. Serious or unstable pre-existing medical conditions or other conditions that could interfere with the patient’s safety, consent, or compliance.
- •10. Pregnant or breastfeeding females.
- •11. Administration of any form of live vaccination (such as influenza vaccine) within 30 days of starting trial and anticipated use during the trial. Administration of any other vaccine is cautionary within 30 days of starting the trial and during the trial.
研究者
相似试验
进行中（未招募）
1 期
Intracerebral Gene therapy in children with Sanfilippo type B syndromeMucopolysaccharidosis III BMedDRA version: 17.0Level: PTClassification code 10056890Term: Mucopolysaccharidosis IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-000856-33-FRInstitut Pasteur
进行中（未招募）
不适用
H-1 Parvovirus for treatment of malignant brain tumors (glioblastoma multiforme)Glioblastoma multiformeEUCTR2011-000572-33-DEOryx GmbH und Co. KG18
已完成
1 期
Intra-cerebral gene therapy for Sanfilippo type B syndromeMucopolysaccharidosisISRCTN19853672Institut Pasteur (France)4
进行中（未招募）
1 期
An effectiveness and safety trial of CTX0E03 Drug Product injected into a patient's brain for the treatment of stable stroke due to reduced blood flow.Supratentorial ischaemic strokeMedDRA version: 20.0 Level: PT Classification code 10061256 Term: Ischaemic stroke System Organ Class: 10029205 - Nervous system disordersEUCTR2012-003482-18-GBReNeuron Ltd21
已完成
2 期
A Study of Modified Stem Cells in Traumatic Brain Injury (TBI)Traumatic Brain InjuryNCT02416492SanBio, Inc.63